Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Evolent Health's accounts receivables for the quarter that ended in Jun. 2026 was $449 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
Evolent Health's Days Sales Outstanding for the quarter that ended in Jun. 2026 was 62.81.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Evolent Health's Net-Net Working Capital per share for the quarter that ended in Jun. 2026 was $-10.08.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Evolent Health's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Evolent Health's accounts receivable are only considered to be worth 75% of book value:
Evolent Health's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Evolent Health Accounts Receivable Related Terms
Evolent Health Accounts Receivable Historical Data
* Premium members only.
The historical data trend for Evolent Health's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evolent Health (EVH) has a Accounts Receivable of $449 Mil as of Jun. 2026. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Evolent Health and its competitors.
Is Evolent Health's Accounts Receivable too high?
Evolent Health's current Accounts Receivable is $449 Mil. Overall, Evolent Health has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evolent Health's Accounts Receivable compare to NRC and CARL?
Evolent Health's Accounts Receivable of $449 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Healthcare Providers & Services company?
A good Accounts Receivable depends on the Healthcare Providers & Services industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Evolent Health and its competitors. Evolent Health's current Accounts Receivable is $449 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolent Health stock overvalued right now?
Based on GuruFocus' analysis, Evolent Health (EVH) is currently considered Possible Value Trap. The stock's GF Value™ is $10.20, compared to a current price of $4.50 — trading 55.9% below its estimated fair value. The current Accounts Receivable is $449 Mil. Evolent Health's overall GF Score™ is 64/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For Evolent Health (EVH), the current Accounts Receivable is $449 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evolent Health (EVH) Overvalued in 2026?
Based on GuruFocus' analysis, Evolent Health stock appears to be undervalued.
The current stock price of $4.50 is trading 55.9% below its estimated GF Value™ of $10.20.
GuruFocus considers Evolent Health to be Possible Value Trap.
Key valuation signals for EVH:
Accounts Receivable: $449 Mil
GF Value™: $10.20 vs. price of $4.50 (55.9% below fair value)
No single metric tells the full story. See the EVH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The solutions provided by the company includes: Oncology, Cardiology, Musculoskeletal, Administrative Services, Advanced Illness, Genetic Testing, Physical Medicine, Radiology, and Surgical Management.
64GF Score
Get the complete analysis for EVH
Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EVH has been successfully added to your 
